Board of Directors
CEO, Founder, and Chairman of the Board
Mr. Legorreta has over 20 years of experience investing in pharmaceutical royalties, and building and managing a rapidly growing life sciences investment company that is today one of the largest dedicated life sciences investors in the world. Prior to founding Royalty Pharma in 1996, Mr. Legorreta was an investment banker at Lazard Frères in Paris and New York. Mr. Legorreta is also a co-founder of Pharmakon Advisors, a leading provider of debt capital to the life sciences industry. Mr. Legorreta serves on the Board of Governors of the New York Academy of Sciences, as well as the Boards of Trustees of the Hospital for Special Surgery, Rockefeller University, Pasteur Foundation (the U.S. affiliate of the French Institute Pasteur), Open Medical Institute, and Park Avenue Armory. Mr. Legorreta is the founder and chairman of Alianza Médica para la Salud, a non-profit dedicated to enhancing the quality of health care in Latin America by providing doctors and healthcare providers with continued education opportunities. Mr. Legorreta has a degree in industrial engineering from Universidad Iberoamericana in Mexico City.
Bonnie Bassler, Ph.D
Bonnie Bassler, Ph.D. has been a member of our board of directors since June 2020. Dr. Bassler currently serves in several roles at Princeton University, including, Chair of the Department of Molecular Biology since 2013, associated faculty member of the Department of Chemistry since 2010, Investigator at the Howard Hughes Medical Institute since 2005, Professor in the Department of Molecular Biology since 1994, and associate faculty member of the Princeton Environmental Institute since 1996. Previously, Dr. Bassler served as the Director of the Council on Science and Technology at Princeton University from July 2008 to June 2013. Dr. Bassler has served as a board member of Kaleido Biosciences, Inc. since 2018, as a board member of Regeneron Pharmaceuticals, Inc. since 2016, and as a Trustee of the Alfred P. Sloan Foundation since 2014, and previously served as a board member of Sanofi from November 2014 to September 2016. Dr. Bassler served as a board member of the American Association for the Advancement of Science from January 2012 to December 2016. She was a member of the National Science Board from January 2010 until May 2016. Dr. Bassler has been elected to the National Academy of Sciences, the National Academy of Medicine, and the Royal Society, among other honorific organizations. She received a B.S. in biochemistry from the University of California-Davis and a Ph.D. in biochemistry from the John Hopkins University.
Errol De Souza, PhD
Dr. De Souza is the Executive Chairman of Bionomics Ltd.. Previously, Dr. De Souza held various management positions at companies including Biodel, Neurocrine Biosciences, Synaptic Pharmaceutical Corp, and Sanofi. Dr. De Souza serves or has served on several editorial boards and National Institutes of Health committees as well as on the board of directors of several private and public companies. Dr. De Souza has a BA in physiology from the University of Toronto and a PhD in neuroendocrinology from the University of Toronto and was a postdoctoral fellow in neuroscience at The Johns Hopkins University School of Medicine.
Cathy Engelbert is the first Commissioner of the Women’s National Basketball Association (WNBA), a position she has held since July 2019. Ms. Engelbert was with Deloitte for 33 years from 1986 through 2019, and held various senior positions, including as a partner serving the pharmaceutical and life sciences practice for over two decades, and then as CEO from 2015 to 2019. Ms. Engelbert currently serves on the board of McDonald’s Corporation and previously served on the board of Deloitte and as the first woman chair of the Center for Audit Quality Governing Board. Ms. Engelbert also served as the first woman chair of the Catalyst Board, a global non-profit organization that promotes inclusive workplaces for women. She was a founding member of the CEO Action for Diversity and Inclusion, is a Vice Chair of the Partnership for New York City and previously served as a member of the Business Roundtable, where she sat on the Education & Workforce and Immigration committees. She received a B.S. in accounting from Lehigh University and is a certified public accountant licensed in Pennsylvania, New York and New Jersey. Ms. Engelbert has been a member of our board of directors since June 2020.
Henry A. Fernandez
Henry A. Fernandez has served as CEO of MSCI Inc. since 1998 and Chairman of its Board since 2007. Before leading MSCI’s transition to becoming a fully independent, public company in 2007, he was a Managing Director at Morgan Stanley from 1983 to 1991 and from 1994 to 2007, where he worked in emerging markets product strategy, equity derivative sales and trading, mergers and acquisitions, worldwide corporate finance and mortgage finance for U.S. financial institutions. Mr. Fernandez serves on the Board of Trustees for Stanford University as well as Memorial Sloan Kettering Cancer Center. Mr. Fernandez holds a Bachelor of Arts in economics from Georgetown University, an M.B.A. from the Stanford University Graduate School of Business and pursued doctoral studies in economics at Princeton University.
William E. Ford
Bill Ford is the CEO of General Atlantic, a leading global growth equity firm. Mr. Ford joined General Atlantic in 1991 and became CEO in 2007. Under Mr. Ford’s leadership, General Atlantic has expanded its global presence, increased its capital base, and deepened its capabilities to identify and partner with high-potential growth companies across multiple business sectors and geographies. Mr. Ford currently serves on the boards of BlackRock, ByteDance and IHS Markit and previously served on the boards of Axel Springer, e*Trade, First Republic Bank, Priceline, and Tory Burch, among others. Mr. Ford is involved with several educational and not-for-profit organizations. He serves as Chair of The Rockefeller University and sits on the boards of EMPEA (Emerging Markets Private Equity Association), Endeavor, and Memorial Sloan Kettering Cancer Center. From 2001 to 2013, he served as a Trustee of Amherst College and currently serves on the Investment Committee for the College’s endowment. Prior to joining General Atlantic, Mr. Ford was an investment banker at Morgan Stanley & Company. Mr. Ford received his BA from Amherst College and his MBA from Stanford Graduate School of Business.
Mr. Giuliani is the former chief financial officer, chairman and chief executive officer of Giuliani SpA. Mr. Giuliani serves or has served on several boards including Giuliani SpA, Giuliani Group SpA, Recordati SpA (incl. Compensation Committee), Nographarma Ltd, Nogra Group SA, HBM Healthcare Investment AG (incl. Compensation Committee), Fair Med Healthcare AG, Jukka LLC USA, NGR (MONACO) SAM, Nogra Pharma Invest Sarl, Nogra Private Equity Sarl, Nogra Real Estate Sarl, Steering Committee for GiSev Family Office SA, and Mosaix Ventures LLP USA. Mr. Giuliani has a degree in economics and commerce from the Catholic University of the Sacred Heart in Milan, Italy.
Ted W. Love, MD
Dr. Love joined Global Blood Therapeutics (GBT) in June 2014 and currently serves as President and Chief Executive Officer and is also a member of the Board. Previously, he was executive vice president, research and development and technical operations, at Onyx Pharmaceuticals, Inc. Prior to Onyx, Dr. Love served as President, Chief Executive Officer and Chairman of Nuvelo, Inc. Prior to Nuvelo, he served as senior Vice President, Development, at Theravance, Inc. Earlier in his career, Dr. Love held a number of senior management positions in medical affairs and product development at Genentech, including as chairman of Genentech’s Product Development Committee and Vice President, Product Development. At Genentech, Dr. Love oversaw the development strategy and execution resulting in approvals of leading therapies such as Rituxan®, Herceptin®, Xolair® and Avastin®. In addition to the Royalty Pharma and GBT Boards, he currently serves on the boards of directors of Amicus Therapeutics, Inc., and the Biotechnology Innovation Organization (BIO). Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School. He completed a residency in internal medicine and a fellowship in cardiology at the Massachusetts General Hospital.
Greg Norden is the former Chief Financial Officer of Wyeth. Mr. Norden also serves on the Boards of Zoetis, the leading animal health company; NanoString, a leading provider of life science tools for translational medicine; and Praxis, a clinical-stage biopharmaceutical company. Mr. Norden is a former director of Human Genome Sciences, Univision and Welch Allyn. In addition, Mr. Norden is the Managing Director of G9 Capital Group, LLC, which invests in early stage ventures and provides corporate advisory services. Mr. Norden has a B.S. in Management and Economics from State University of New York at Plattsburgh and an M.S. in Accounting from LIU Post.
Mr. Riggs co-founded Royalty Pharma in 1996 and assumed the role of chairman in 2003. Mr. Riggs is the founder & CEO of Syntax & Locus Analytics. Previously, Mr. Riggs was President of Biomatrix. Mr. Riggs serves or has served on several boards including Fibrogen, Cibus, Sugen, Intra-cellular Therapies and Biomatrix. Mr. Riggs has a BA from Middlebury College and an MBA from Columbia University.